ATE419346T1 - Hemmung der bildung von atherosklerotischen wunden mittels afabp antisens nukleinsäuren - Google Patents

Hemmung der bildung von atherosklerotischen wunden mittels afabp antisens nukleinsäuren

Info

Publication number
ATE419346T1
ATE419346T1 AT00908604T AT00908604T ATE419346T1 AT E419346 T1 ATE419346 T1 AT E419346T1 AT 00908604 T AT00908604 T AT 00908604T AT 00908604 T AT00908604 T AT 00908604T AT E419346 T1 ATE419346 T1 AT E419346T1
Authority
AT
Austria
Prior art keywords
afabp
atherosclerotic
formation
wounds
inhibition
Prior art date
Application number
AT00908604T
Other languages
English (en)
Inventor
Edgar Haber
Mu-En Lee
Mark Perrella
Gokhan Hotamisligil
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Application granted granted Critical
Publication of ATE419346T1 publication Critical patent/ATE419346T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT00908604T 1999-02-12 2000-02-11 Hemmung der bildung von atherosklerotischen wunden mittels afabp antisens nukleinsäuren ATE419346T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11988099P 1999-02-12 1999-02-12

Publications (1)

Publication Number Publication Date
ATE419346T1 true ATE419346T1 (de) 2009-01-15

Family

ID=22386964

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00908604T ATE419346T1 (de) 1999-02-12 2000-02-11 Hemmung der bildung von atherosklerotischen wunden mittels afabp antisens nukleinsäuren

Country Status (8)

Country Link
US (1) US20090012020A1 (de)
EP (1) EP1151092B1 (de)
JP (1) JP2002536459A (de)
AT (1) ATE419346T1 (de)
AU (1) AU781295B2 (de)
CA (1) CA2361335A1 (de)
DE (1) DE60041246D1 (de)
WO (1) WO2000047734A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0932201A (ja) * 1995-07-15 1997-02-04 Hotta Carpet Kk 土木建築積層体
US7056662B2 (en) 2000-02-17 2006-06-06 President And Fellows Of Harvard College Method of diagnosing a risk of developing insulin resistance
AU2002345932A1 (en) * 2001-06-26 2003-03-03 San Diego State University Foundation Compositions and methods for treating atherosclerosis
US7262017B2 (en) 2001-09-14 2007-08-28 Torrey Pines Institute For Molecular Studies Diagnostic markers for ischemia
AU2005227312B2 (en) 2004-03-22 2011-04-07 Ffa Sciences, Llp Development and use of fluorescent probes of unbound analytes
US20060257938A1 (en) * 2005-05-10 2006-11-16 Kleinfeld Alan M Method of screening for drugs that block ligand binding to a lipid binding protein
WO2008060841A2 (en) 2006-10-27 2008-05-22 Ffa Sciences, Llc Use of probes for unbound metabolites
SI2403605T1 (sl) 2009-03-05 2015-11-30 President And Fellows Of Harvard College Sestavki, ki obsegajo aP2-specifično protitelo ali njegov fragment, za uporabo pri zdravljenju diabetesa, intolerance za glukozo ali z debelostjo povzročene inzulinske rezistence
EP3288584A2 (de) 2015-04-30 2018-03-07 President and Fellows of Harvard College Anti-ap2-antikörper und antigenbindemittel zur behandlung von stoffwechselerkrankungen
PL3416684T3 (pl) * 2016-02-17 2023-11-06 Regeneron Pharmaceuticals, Inc. Sposoby leczenia lub profilaktyki miażdżycy tętnic przez podawanie inhibitora angptl3
MA43734A (fr) 2016-03-03 2018-11-28 Regeneron Pharma Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3
WO2018227200A1 (en) 2017-06-09 2018-12-13 President And Fellows Of Harvard College Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies
US12084419B2 (en) 2020-06-27 2024-09-10 Crescenta Biosciences Cell metabolism modulating compounds and uses thereof
US12138243B2 (en) 2021-12-31 2024-11-12 Crescenta Biosciences Antiviral use of FABP4 modulating compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019841D0 (en) * 1990-09-11 1990-10-24 Smith Kline French Lab Compounds
WO1992006104A1 (en) * 1990-09-28 1992-04-16 The Dana-Farber Cancer Institute Adipocyte-specific dna sequences and use for the production of transgenic animals exhibiting altered fat metabolism
US5254576A (en) * 1992-04-03 1993-10-19 Bristol-Myers Squibb Company Diphenyl-heterocyclic-oxazole as platelet aggregation inhibitors
WO1998045440A1 (en) * 1997-04-08 1998-10-15 Incyte Pharmaceuticals, Inc. Human fatty acid binding protein
GEP20033044B (en) * 1998-09-17 2003-08-25 Bristol Myers Squibb Co Method for Treating Atherosclerosis

Also Published As

Publication number Publication date
WO2000047734A1 (en) 2000-08-17
JP2002536459A (ja) 2002-10-29
EP1151092A1 (de) 2001-11-07
DE60041246D1 (de) 2009-02-12
US20090012020A1 (en) 2009-01-08
AU2991300A (en) 2000-08-29
EP1151092B1 (de) 2008-12-31
AU781295B2 (en) 2005-05-12
CA2361335A1 (en) 2000-08-17

Similar Documents

Publication Publication Date Title
ATE419346T1 (de) Hemmung der bildung von atherosklerotischen wunden mittels afabp antisens nukleinsäuren
BR9806752A (pt) Ftalazinonas.
FI971489A0 (fi) Uusia bentsoksatsoleja
ATE318267T1 (de) Einige alkylendiamin-substituierte heterocyclen
WO2001081312A3 (en) Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
CY1115870T1 (el) Ενωσεις 1,2,4-οξαδιαζολο βενζοϊκου οξεος και χρηση αυτων για μη νοηματικη καταστολη και τη θεραπεια ασθενειας
WO2001078711A3 (en) Pde-v inhibitors for treatment of parkinson's disease
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
MXPA03006855A (es) Metodo para tratar insuficiencia cardiaca cronica y/o niveles elevados de colesterol, utilizando acido 3,5-diyodotiropropionico, y metodo para su preparacion.
DE60012751D1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
NO20010718D0 (no) Ny saltform av pantoprazol
ATE293450T1 (de) Verwendung von biphosphonsäuren zur behandlung von angiogenese
PE20011085A1 (es) Compuestos isoxazolquinolin o imidazolquinolin como inhibidores de la proteina resistente a multifarmacos
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
SE9801494D0 (sv) Novel use
ATE372114T1 (de) Verfahren zur erhöhung des testosteronspiegels
ES2147973T3 (es) Estirenos alquilatados como profarmacos de inhibidores de cox-2.
DE69924146D1 (de) Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen
EA200100930A1 (ru) Способ лечения хозл
ECSP003590A (es) Compuestos calcioliticos
SE0002739D0 (sv) New use
ATE315387T1 (de) Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties